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Prescription hypnotics in the news: a study of UK audiences 
 
Abstract 
In 2012 the UK media reported the results of a paper in the British Medical Journal Open, 
including the finding that hypnotics increase the risk of ‘premature death’. Taking this media 
coverage as a case study, the paper explores UK people’s responses and assesses the 
implications for the debate about the (de)pharmaceuticalisation of sleep. Two hundred and 
fifty one posts to the websites of 6 UK newspapers were analysed thematically, along with 12 
focus group discussions (n=51) of newspaper coverage from one UK newspaper. Four 
thematic responses were identified: bad science/journalism, Hobson’s choice, risk assessment 
and challenging pharmaceuticalisation. We found that most people claimed that the story did 
not worry them, even if they stated that they were using sleeping pills, and that focus group 
members generally appeared to respond in terms of their pre-existing views of hypnotics. The 
way in which lay expertise was drawn on in responding to the coverage was one of the most 
striking findings of the study. People referred to their own or others’ experience of taking 
hypnotics to recognise the legitimacy of taking them or to weigh up the risks and benefits, as 
reflexive users. Overall, our case study cautions against making strong claims about the 
power of the media to legitimate de-pharmaceuticalisation. While the media may have such a 
role, this is in the main only for those who are receptive to such a message already. 
Abstract: 233 words.  Main body of article: 9585   
Key Words: United Kingdom, De-pharmaceuticalisation, sleeping pills, mass media, 
audience responses 
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Prescription hypnotics in the news: a study of UK audiences 
 
Introduction 
Sleep is in the news for all sorts of reasons these days. Scarcely a day goes by without some 
sleep-related story appearing on life in a ‘chronically sleep deprived society’, from the 
stresses and strains of living in a wired 24/7 world to excessive daytime sleepiness (Kroll 
Smith 2003, Seale et al 2007, Williams 2005, Williams et al 2008). 
One important strand and long-running saga here concerns media coverage of sleep 
medicines, particularly prescription hypnotics or sleeping pills, which have tended over time 
to receive a bad press (Gabe and Bury 1988, 1991, 1996a, 1996b). For example, after a 
generally enthusiastic welcome in the 1960s, benzodiazepine sleeping pills have been 
increasingly criticised for causing addiction, dependence and even psychosis, and as 
examples of a ‘pill-popping way of life’ (Montagne 1991). 
In this paper we shed further critical light on these matters, with particular reference to 
debates on the (de)pharmaceuticalisation of sleep, taking recent media coverage of a British 
Medical Journal Open article on the raised mortality risks of long-term prescription 
hypnotics as our case study. In contrast to much previous work of this kind, our focus here is 
on people’s responses to this breaking, newsworthy storyline, through online posts and follow 
up focus groups. Key questions include the following: how did readers process this story? did 
they feel more concerned about taking sleeping tablets as a result of this news report, did they 
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dismiss such a report as an example of media exaggeration, and did they respond according to 
their pre-existing views about the merits (or otherwise) of taking such medications?  
The paper, as such, is dually situated at the nexus of newly emerging and long overdue 
attention to sleep matters in the social sciences, medically related or otherwise, and other 
recent debates in sociology and cognate fields regarding the ‘pharmaceuticalization’ of life 
(Abraham 2010, Williams et al 2011, Bell and Figert 2012), of which sleep of course is a 
vital part. Our focus in this paper is on the extent to which media coverage of the negative 
effects of sleeping tablets might contribute to the de-pharmaceuticalisation of sleep. Before 
we consider our data on this issue we review the literature on the pharmaceuticalisation of 
sleep and discuss the case study and methods underpinning our study. 
The pharmaceuticalisation of sleep 
Pharmaceuticalisaton has been employed as an explanatory concept in the social sciences for 
some time, being first used in anthropology by Nichter in 1989 (cited in Bell and Figert 2012) 
and in sociology by Abraham in 2007 (Abraham 2007,  Gabe et al 2015). It refers to a 
process whereby human conditions, capabilities and capacities are translated into 
opportunities for pharmaceutical intervention (Williams et al 2011). While overlapping with 
medicalisation (the use of pharmaceuticals as treatment is a feature of both theories and both 
recognise that doctors can be gatekeepers for medications) pharmaceuticalisation is distinct in 
that it encompasses the non-medical use of pills (e.g. for lifestyle, recreation or enhancement 
purposes) and access to them from outside the medial arena (including over-the-counter 
purchases to procurement on the Internet and black market). Relations between 
pharmaceuticalisation and medicalisation are therefore complex and contingent (Williams et 
al 2011), especially in the case of sleeping pills, which are predominately under medical 
control as prescription medications.  
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 A key conveyor or amplifier of the process of pharmaceuticalisation, according to Williams 
et al (2011), is the mass media who may celebrate the introduction of new drugs, publicise 
particular pharmaceutical regimes and generate various levels of public support for their 
adoption (Biehl, 2007). For instance, as noted above, the media in the US and UK gave 
benzodiazepine sleeping pills an enthusiastic welcome as a new drug heralding a new era 
when they first arrived on the market in the 1960s (Gabe and Bury 1996b). Similarly, others 
have found media coverage of new (cancer) drugs to be biased in favour of reporting benefits, 
indeed perhaps even overemphasising or exaggerating these, to the exclusion of non-
pharmaceutical therapeutic options (Davis, 2015). However, once potential dangers in the 
form of side effects or misuse have been detected, media coverage often takes a more critical 
stance (Williams et al 2011). Sleeping pills, particularly benzodiazepines, have received a 
‘bad press’ for many years, being associated with side effects, dependence and addiction. The 
role of the mass media in conveying processes of de-pharmaceuticalisation through such 
‘scare stories’ highlighting dangers and risks associated with pharmaceutical use has not, to 
our knowledge, been examined empirically to date. 
While a major focus has been on the growth in pharmaceuticalisation, particularly in OECD 
countries, the process should be viewed as bi-directional; in other words it is also possible for 
de-pharmaceuticalisation to take place (Williams et al 2011). For example, doctors and/or 
patients/health consumer groups might advocate a drug’s withdrawal and replacement with 
non-drug therapies, and this critical stance might be legitimated by the mass media, as 
happened with the benzodiazepines in the 1980s and 90s (Gabe and Bury 1988, 1996b). 
While it is more likely in practice for a new generation of drugs to replace a previous 
generation rather than being phased out as an area of intervention, the latter remains a 
possibility (Gabe et al 2015). And of course there is evidence of resistance to pharmaceuticals 
and pharmaceuticalisation amongst lay people (e.g. Pound et al 2005; Murdoch et al 2013), 
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who may demonstrate a sophisticated `lay pharmacology’ about the safety, efficacy and side 
effects of prescribed medications (Webster et al 2009). 
In the case of sleep there is considerable evidence that Britons are suffering from sleep 
problems for which a medical solution might be sought. It has recently been reported that up 
to one third of Britons are suffering from insomnia at any one time, and that at least one in 
ten can be characterised as a chronic insomniac (MHF 2011). Having sleep problems also 
seems to be a persistent issue with 74% in a longitudinal study reporting continuing problems 
one year on and 46% claiming these difficulties three years on. In a UK study of 17,000 
respondents, one third reported that they had less than 6.5 hours sleep a night on average and 
12% indicated that they regularly had less than 6 hours sleep a night (Understanding Society 
2011). 
Faced with such sleep problems it is perhaps not surprising that people have turned to doctors 
for advice and, as a result, have frequently been prescribed a hypnotic. It has been reported 
that around a tenth of people aged 16 and over take sleeping tablets three or more times a 
week (9% men and 10% women) and the likelihood of taking such a medication increases 
with age, although varying by gender (Understanding Society 2011). For example, in the 
recent Understanding Society survey, 25% women and 15% men over 85 years of age 
reported taking a hypnotic three or more nights a week, although this included both 
prescription and over-the-counter medications. Interestingly, current rates of hypnotic 
prescribing in the UK are less than they were 35 years ago (13.6 million prescriptions for 
hypnotics were issued in 1980, source: Morgan and Clarke, 1997). While there was a marked 
increase in prevalence between 1993 and 2000, rates remained stable between 2000 and 2007 
at around 10 million items prescribed per year (Calem et al 2012), although they have been 
declining a little more recently (to around 9.5 million items in 2014, HSCIC, 2015).   
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The market for sleeping tablets in the UK has traditionally been dominated by the 
benzodiazepines like temazepam and nitrazepam but these have now been replaced as market 
leaders by the so-called Z drugs like Zopiclone and Zolpidem. In 2014 almost 6.5 million 
prescriptions for z drugs were dispensed (primarily Zopiclone) and nearly 2 million 
benzodiazepines were prescribed as sleeping tablets (temazepam being the market leader with 
1.7 million prescriptions) (HSCIC 2015). The majority of these sleeping tablets have been 
prescribed for four weeks or more; that is contrary to guidance from the UK National 
Institute for Healthcare Excellence (NICE 2004), which has consistently warned about the 
dangers of dependence on these medications, especially the benzodiazepines. Similar advice 
about the dependence potential of benzodiazepines, including as sleeping tablets, was issued 
by the UK Department of Health and Social Security in the 1980s (Gabe and Bury 1988). 
Faced with such concerns, attention has been focused recently on non-pharmaceutical 
treatments and whether they might be as/more successful than medications. There is some 
evidence that cognitive behavioural therapy (CBT) can be successful (Morin et al, 1999, 
2006) though this has still has to be endorsed by NICE, through a national insomnia treatment  
programme, despite lobbying for such guidance (NICE 2010). CBT is also part of the UK 
government’s programme for Improving Access to Psychological Therapies (IAPT) in 
England, suggesting that there has been some modest encouragement for de-
pharmaceuticalisation. However, as the prescription rates suggest sleeping tablets still seem 
to be favoured by many patients and their doctors. 
This evidence of the use of hypnotics and the possibility of alternative forms of therapy 
provides the context for our research into the role the mass media play in the de-
pharmaceuticalisation of sleep.  In our analysis we consider one aspect of this, namely, how 
people respond to media coverage of the reported risks of hypnotics. In what follows we 
assume that audience readings of such texts and/or reactions to them are made in relation to 
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their biographies and the constraints of their daily lives; what Bloor (1995) has called the 
situated rationality approach to risk. Responses are likely to be diverse rather than uniform 
and may demonstrate resistance as well as alignment with dominant ideas. Certainly there is 
evidence that users of sleeping tablets often feel ambivalent about taking them, seeing them 
as representing an unnatural interference with a natural state and associating their use with 
loss of control and addiction (Cheung et al 2015, Davy et al 2013, Gabe and Lipshitz-Phillips 
1984, Gabe and Thorogood 1986, Venn and Arber 2012). Some users may thus respond to 
media coverage of sleeping tablets as bolstering their resistance to taking these drugs, while 
other users may reject the alleged risks of taking them and continue to assert that they need 
them, while non-users may be expected to take a more avowedly critical stance and accept 
the risks of use as not only too great but as a sign of moral weakness.  In this way 
respondents are likely to draw on particular repertoires to justify and legitimate hypnotic 
use/non-use in the management of sleep problems such as the ‘deserving user’, the 
‘responsible user’, and the ‘addict’ (Gabe et al 2016). By ‘repertoire’ we mean a relatively 
coherent system of meanings for ‘characterizing and evaluating actions, events and other 
phenomena’ (Potter and Wetherell 1987: 149). 
 
Whatever their response it is assumed that audiences for such messages should be seen as 
active rather than passive (Seale 2004). As Webster (2014: 120-1) argues, ‘audiences do not 
straightforwardly absorb messages. Instead they interpret them, bringing to them values and 
meanings gleaned elsewhere’. Moreover they interact with these messages, to ‘challenge, 
expand, reject or embrace’ them. This is certainly likely to be the case where people have the 
opportunity to react online to what they have been reading on the Internet.  
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Media Case Study and Methods 
We start with a brief account of the story and the media response before discussing the 
methods we used to explore how the public and focus group members responded to the story. 
The value of the case study approach is also considered.  
Media Case Study 
On 28 February 2012 the UK media gave particular coverage to an article in the British 
Medical Journal Open (Kripke et al 2012) about the negative effects of taking prescribed 
hypnotics. Newspapers, television news programmes and websites all reported the study 
findings, often using eye catching headlines. This paper considers how coverage of this news 
story on websites of UK national newspapers and the British Broadcasting Corporation 
(BBC) resulted in a series of posts over eight days from the story’s publication, and 
subsequently how members of focus groups viewed such reporting. The findings are 
considered in the context of the debate about the pharmaceuticalisation and de-
pharmaceuticalisation of sleep. 
The BMJ Open article was based on a large study in the United States which had compared 
medical records of 10,000 people who had been prescribed sleeping pills over 2.5 years, on 
average, with 23,000 who reportedly had never received a prescription for such drugs. Those 
prescribed sleeping pills, even at very low doses, were found to be more likely to die than 
those who had not been prescribed these pills. Those prescribed high doses (more than 132 
pills a year) were also more likely to develop cancer than non-users. Overall, however, the 
authors of the study admitted they could not tell if the medicines themselves were a direct 
cause of higher rates of death or cancer as it was possible that both the use of sleeping tablets 
and the risk of death could be associated with lifestyle factors. 
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UK newspaper coverage included a variety of headlines, ranging from the broadsheets which 
noted `Safety concerns over sleeping pills taken by millions’ (Daily Telegraph) and `Sleeping 
pills increase risk of death, study suggests’ (The Guardian) through to tabloid newspapers 
that claimed `Sleeping pill users “up to five times more likely to die early”’ (Daily Mail) and 
`Sleeping pills can be lethal’ (The Sun). On the BBC News website the headline was 
‘Sleeping pills “linked to increased death risks”’ (BBC News). 
The Daily Mail article can be taken as an example of this media coverage. It was chosen 
because it was accessible to all, unlike the broadsheet articles, and had generated the most 
posts amongst the tabloids. Although not directly advising hypnotic users to stop taking this 
medication, this article  can be seen as promoting a de-pharmaceuticalisation agenda, 
focusing on the possible risks and negative side effects of hypnotic medication whilst 
reporting non-pharmaceutical alternatives to insomnia management (such as CBTi) in a more 
favourable light. Concerned patients are then advised to discuss their medication use with 
their GP. The article ends with a short statement from a leading British expert in clinical 
psychopharmacology who is quoted as saying “I agree these drugs do have problems, but I 
find some of these results difficult to accept. The main one is that with 18 doses a year you 
have three times the mortality – that's quite incredible, because you would have people 
dropping like flies”. 
Faced with these headlines how did audiences of the UK national media respond with online 
posts (referred to from this point as ‘posters’) and how did those who were subsequently 
shown the Daily Mail coverage in focus group discussions react? In particular did they 
respond in such a way as to suggest that this coverage was encouraging a process of de-
pharmaceuticalisation? 
Methods 
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Following the reporting of the BMJ Open paper in the online version of the UK media on 28 
February 2012, all posters’ comments linked to this coverage up to 6 March (eight days in 
total) were included in the sample, totalling 293 comments. These posts appeared on the 
websites of 6 newspapers (see table 1). 
    Table One about here 
Comments not directly relevant to the content of the newspaper story (for example spam 
messages or arguments between posters diverging from the content of the article) were 
excluded, reducing the sample to 255 posters’ comments. Exchanges between posters were 
included where relevant. The sample incorporates occasional multiple posts from the same 
user. It is not known exactly how many people responded to these stories as they could have 
used different user names to post messages. Nor is the background of posters known, unless 
they revealed such information. It is possible that some of the posters may have resided 
outside the UK as geographical location was only mentioned by them infrequently. It may 
also be the case that some posters wrote what they did in order to appear knowledgeable in 
front of other posters rather than express authentic feelings.  The fact that most posters used 
pseudonyms makes such impression management less likely but does not exclude it 
completely.  Posters are also a self-selected group although we do not see this as a problem 
given our case study approach (see below). Analysis of the posts was undertaken 
thematically, systematically identifying different topics in the data, probing the disposition of 
the poster (whether favourable or hostile to the storyline) (Bryman 2012) and undertaking 
frequency counts. 
In addition, an example of newspaper coverage of the story, from the Daily Mail (described 
above), was discussed in focus groups with people who might be expected to have particular 
views on sleep and its management. We purposively selected these groups in order to explore 
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diversity in experiences of and attitudes towards sleeping pills rather than for 
representativeness. The focus group was chosen as the preferred method as we were 
interested in how people discussed sleep and sleeping pills collectively and the normative 
understandings underlying such processes (Bloor et al 2001). A particular advantage of the 
focus group method is that the participant’s point of view is much more likely to be revealed 
than in a traditional interview, because s/he has more ownership of the research process. On 
the other hand there are potential problems with ‘group effects’, especially whether group 
norms lead to more agreement than one might expect to be the case (Morgan 1997) and the 
possibility that participants may be prone to expressing culturally expected views (Bryman 
2012). In the study reported here the pressure to express expected views about the media 
story may have been moderated by the scheduling of this topic late in the focus group, when 
impression management might have been less of an issue. 
Following ethics approval from the National Health Service in England, we held 12 focus 
groups with 51 participants between 2012 and 2014 who discussed the Daily Mail article (a 
further eleven groups did not consider the article). Focus groups ranged from those recruited 
from primary care who had been long term users of hypnotics (3 focus groups, 12 
participants) to residents of a retirement complex (3 focus groups, 15 participants) to parents 
of young children (one group, 6 participants). Focus groups were also held with medical 
students (one focus group, n=3), university lecturers (two focus groups, n=8), lawyers (one 
group, n=3) and those suffering from narcolepsy (one focus group, n=4).  The size of the 
group did not seem to have any bearing on the content of the talk generated. 
Research participants were recruited in a number of ways. General practice patients were 
invited to participate by their GP, on the basis of having received a prescription for sleeping 
tablets. Those attending the narcolepsy clinic were asked to contact the researchers if they 
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were interested in being part of the research by the clinician in charge of the clinic. Students 
were recruited through the local university student union, departmental student lists and 
personal contacts.  Parents of young children were recruited through local parent and toddler 
groups. The focus groups made up of academics and lawyers were formed through personal 
contacts. Those who lived in the retirement complex were invited to participate via a 
gatekeeper who lived on site. All participants were given an information sheet in advance, 
explaining that their comments would be anonymised and that they could withdraw from the 
study at any time without giving a reason. Written informed consent was provided by all 
participants.  
The resulting 12 focus groups were reasonably diverse in terms of age, with about 55% of the 
sample being 45 years of age or over. Around 70% of participants were female and over 90% 
identified as of white British or Irish ethnicity. Over half the sample (60%) had, or had 
previously had before retirement, a higher managerial or professional job.   
(Table Two about here) 
In each of these focus groups we asked participants to discuss how they managed sleep 
problems in their daily lives, including whether they used hypnotics, as well as their views of 
the newspaper story.  Towards the end of each focus group session we handed out the media 
story to participants and asked them to look at it and tell us what they thought. Thirty one 
participants, across the 12 focus groups, disclosed current or previous use of prescription 
hypnotic medications. Of these almost three quarters were members of the primary care or 
retirement complex focus groups. Not surprisingly it was those from the primary care and 
retirement complex focus groups who were the ones who could remember having read or 
heard reports of the BMJ Open paper in the media.  
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Focus groups were audio recorded and transcribed.  Analysis of the transcripts was facilitated 
using the qualitative data analysis software package NVivo 10. We took an inductive 
approach to data analysis, which involved reading and re-reading the transcripts, grouping 
data extracts together based on the main themes and developing a coding frame based on 
these emergent themes to identify major topics and issues. Codes and themes relating to 
major issues were discussed between the authors for purposes of reliability and validity. 
These were used to develop an interpretative analysis of the meaning of the newspaper 
coverage about the BMJ Open article and to address the research questions outlined above. 
 
Subsequently each focus group member was given an identifying code, indicating the type of 
focus group they had participated in, the number of the group and the gender of the 
participant, and the sequence in which they first spoke in the focus group (for example, 
PCFG1F1 indicates Primary Care Focus Group 1, Female 1).  
 
We have chosen a case study approach as it is useful in exemplifying ‘the circumstances and 
conditions of an everyday or commonplace situation’ (Yin 2009: 48). In our case the 
commonplace situation is how people reacted to the media story about the negative effects of 
sleeping tablets. The case study approach also provides a suitable context for addressing our 
research questions (Bryman 2012). No claim is being made for the representativeness of the 
posters and focus group members. Rather ‘the validity of the extrapolation depends ...on the 
cogency of the theoretical reasoning’ (Mitchell 1983: 207) and the extent to which the data 
support this reasoning.   
 
Finally we should mention two limitations of our study before proceeding. First it should be 
noted that while we have a baseline understanding of how focus group members thought about 
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hypnotics before reading the news report, as they had already expressed their views about these 
pills before being introduced to the coverage in the Daily Mail, this is not the case with the 
posters.  We do not know what they thought of sleeping pills before posting their comments 
online. Second, it is possible that there were readers of the news report who accepted its de-
pharmaceuticalisation framing but decided not to post. Those individuals who did not post their 
thoughts after reading the article may be the ones most likely to have felt they had 'learned' 
something or accepted the articles’ general stance and content whilst those disagreeing might 
have been more motivated to put their alternative viewpoint across. It is impossible to know 
whether this was so as we only have data from posters, but there were a sizeable number of such 
posters who did embrace this de-pharmaceuticalisation framing. Below we consider posters and 
focus group members’ reaction to this media story in terms of different responses.   
 
Reactions to the media story online and in focus groups 
Four main responses were employed by people in posts or focus group discussions when 
assessing the media coverage of the BMJ Open paper. These were: i) To dispute the validity 
of the information presented – by claiming that it illustrated what we have called ‘bad 
science/journalism’; ii) To emphasise the crucial role that hypnotics played in enabling them 
to keep going or even survive – in this sense they had no choice but to use hypnotics – 
Hobson’s choice; iii) To assess the risks and benefits of using sleeping tablets, reflecting a 
range of views around risk avoidance and risk taking; and iv) To elaborate the negative 
message of the media reporting and/or suggest non-drug alternatives. Participants variously 
called on repertoires of the ‘deserving user’ (in distress and in need of help), the ‘responsible 
user’ (who used their medication appropriately) and the ‘addict’ (who was escalating use and 
losing control over their medication and themselves) in their response to the media story 
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(Gabe et al 2016). Posters were assigned to only one of these responses on the basis of their 
posts, as were the great majority of focus group members given their comments.  
Beside the four major themes outlined here 37 posts were on other topics. Some focused on 
sleep and lifestyle with sleep being seen as a virtue. Posters talked about how important sleep 
was and how lifestyle factors such as stress, diet and exercise can affect sleep either 
negatively or positively. Other posts were concerned with clarifications or corrections, for 
example about safety issues or regulation or contained criticisms of other posters for the 
stance they had taken. No other themes were mentioned in the focus groups. 
 
Below we consider the four main responses in turn.   
 
i) ‘Bad’ Science/Journalism 
This represents the biggest category of posts (n=70) and comments by focus group members 
(n=26). Interestingly posters often sought to develop a sophisticated methodological critique 
of the study published in the BMJ Open as ground for questioning the validity of the findings. 
Some recognised that a correlation was not the same as causation or that hypnotic drug use 
was best seen as a proxy for an underlying ‘disease state’. Others saw the coverage as 
reflecting a failure by journalists to take a critical stance and interrogate the statistics, 
resulting in scare mongering. 
For example, consider a post on The Guardian website: 
‘Hypnotics represent a valuable aid to individuals during times of distress. Disrupted 
sleep is one of the commonest symptoms complained of by those with depression. 
Those with physical conditions in general hospital often request sleeping aids as well. 
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This case controlled study makes no attempt to control for mental state, or disease 
severity, so disrupted sleep, requiring hypnotic prescription, could just indicate 
disease severity, or a co-morbid mental health problem, both of which could also raise 
mortality’. 
The complex nature of this critique makes one wonder about the background of the posters 
and the extent to which they had a vested interest in the prescribing of sleeping tablets. 
In comparison with the above, focus group members were generally less sophisticated in their 
comments and focused primarily on the sensationalist nature of reports in the tabloid 
newspaper running the story and their lack of trust in the story as a result. The focus on 
sensationalism is not perhaps surprising given the nature of tabloid coverage (Seale 2002), 
yet even the Daily Mail provided readers with enough information about risk to make an 
assessment of the validity of the claim.  In some cases the lack of trust reported was linked to 
the focus group members’ view that statistics can be manipulated.  
‘Well the first thing, just looking at this ..... I don’t believe anything the Daily Mail 
says. And sleeping tablets, “you are five times more likely to die early”. .. Five times 
more likely than what? I mean statistics, anything like that. I would just question what 
it means. I wonder how much of it is selective by the Daily Mail because a number of 
times I’ve got things from the Daily Mail that are just plain wrong. .. If it had been 
(the broadsheet papers) The Times, The Guardian, The (Daily) Telegraph even, I 
think I might make a bit more of it. But I don’t believe anything from the Daily Mail.’ 
(Primary Care FG3, Male 1) 
A few wondered if the study had controlled for other conditions or mentioned the distinction 
between cause and correlation but seemed to lack the degree of statistical knowledge 
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demonstrated by the posters. Consider, for example, the comment of a participant in an 
academic focus group: 
‘The fact that it is in the Daily Mail does frame my reaction….the impression I get is 
science reporting, even in publications that I read like the Guardian, is not great. I’m 
not a trained scientist but I’m vaguely aware of issues of correlation and cause and 
listening regularly to the (BBC) Radio Four programme about statistics, I’m aware of 
how a small quirk in analysis can actually create the impression. This phrase at the 
end [from a leading expert in clinical psychopharmacology] about, well you know, if 
that was the mortality rate people would be ‘dropping like flies’ precisely suggests 
that phrases like ‘five-fold increase’ and so on are misleading. They might be 
technically correct but I think there is a sort of general default position which is that 
every given day a newspaper, especially the Daily Mail, will blame something for 
cancer… So actually I would be quite relaxed I think. I mean I’m not on any 
medication but I think that I would actually take this as an unnecessarily alarmist 
treatment of research which seems relatively inconclusive.’ (Academic FG 1, Male 1) 
This respondent was clearly sceptical of media reporting in general, and in the Daily Mail in 
particular, and used his limited lay knowledge of statistics, itself informed by a radio series, 
to justify dismissing the story as unnecessarily alarmist. As he illustrates, such views were 
not limited to those taking hypnotics but reflect a general scepticism of people about the 
validity of the claims in the media, including in the tabloids. This response reflects what 
Collins (2014) has described as ‘ubiquitous meta expertise’, using logic rather than technical 
knowledge to challenge a media story. 
As we also see in the extract above, it was common for those rejecting the content of the 
article to connect with and repeat the expert in clinical psychopharmacology’s quote that 
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should the statistics presented be accurate, people would be ‘dropping like flies’. It is 
interesting how those taking this stance accepted the reporting of a statement by one expert, 
as it affirms their own stance or beliefs (regarding the publication, the medication or the 
statistics), while the presentation of research findings of others are questioned or rejected. We 
can see here then, how readers are both active and selective in their processing of media 
information. 
 
ii) Hobson’s Choice 
For posters in this category (n=36) sleeping tablets were not just beneficial, they were crucial 
in helping them to keep going or in some cases simply enabling them to survive. In 
developing this viewpoint they drew on experiential knowledge and the repertoire of the 
‘deserving user’ (Gabe et al  2016).  For them going without these drugs would make them 
`go crazy’. Some combined an emphasis on the drug enabling them to survive with the 
benefits for public safety and for society. By taking sleeping tablets and acting as 
‘responsible’ users they avoided the risk of an accident and were able to hold down a job. In 
the latter case public health messages about responsibilization  (Rose 1999) were being 
inverted and used to justify taking pills regularly, in contrast to the advice of bodies such as 
NICE. 
Take, for example, the following post in The Guardian: 
‘As a chronic insomniac for over 25 years I have been on and off sleeping tablets for 
years, been to sleep clinics, had CBT and tried almost everything on the market. I can 
go for days without sleep which is unbearable for myself, colleagues and family as it 
has caused me to have constant depression and anxiety. I do not drive due to the 
effects of Zolpidem which is a pain but, if my little white pill (half now as I have cut 
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down) helps me to function on a daily basis, hold down a job and live a relatively 
normal life and my life is cut short because of it, so be it. Tiredness is more of a killer 
in my view.’ 
We see here how non-pharmaceutical treatments are acknowledged, the poster has ‘been to 
sleep clinics’ and ‘had CBT’, and subsequently dismissed as a viable alternative to the 
pharmaceuticalisation of sleep.  
Such meanings were present but found to a much lesser extent in focus group discussions of 
the newspaper report.   The example below comes from one of the retirement home focus 
groups where the participant draws on the repertoire of the ‘deserving user’ in arguing that 
hypnotics had an important role in the management of sleep problems for those who were 
desperate, as follows: 
‘You’ve got to think of the effect that insomnia has on a person’s family. I mean if 
you have got someone walking the street or walking the floor all night, when they 
don’t live on their own, because they can’t sleep, I mean it’s very disturbing to put it 
mildly. So there’s a place for them’. (Retirement FG 3 Female 2) 
 Thus posters and focus group members who emphasised the necessity of sleeping tablets in 
response to the media coverage of the BMJ Open article were in effect resisting the de-
pharmaceutical agenda being supported in such coverage.  
  
iii)  Risk Assessment 
In addition to talk about resisting, rebuffing or questioning de-pharmaceuticalisation there 
was also discussion of the risks as well as the benefits of sleeping tablets. Posters employing 
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this risk language (n=66) talked freely about particular hypnotic drugs they had used and 
gave advice about them. As such they could be characterised as offering a risk/benefit 
analysis, in line with Webster et al’s (2009) concept of ‘lay pharmacology’. For some the risk 
was worth taking whereas for others it was too risky. This group thus contained both those 
who were supportive of pharmaceuticalisation and others who were in favour of de-
pharmaceuticalisation or at least restricting pharmaceuticalisation. 
Below are examples of an exchange between posters which illustrate both positions, starting 
off with one who felt the risks were worth taking, drawing on the ‘deserving’ repertoire. The 
second poster takes the opposite position, drawing on an ‘addiction’ repertoire and 
advocating limited use at best:  
‘Another scare story you would expect to find in the Mail! I have had trouble sleeping 
for years. I’ve tried everything. The only thing that works for me is a mild German 
tablet called Lendormin. Perfect! I have regular check-ups (blood etc.) and everything 
is OK. Anybody else had any experience of this particular life saver?’ 
‘Brotizolam (aka Lendormin) is not licensed in the UK – or the USA. It’s not 
particularly mild, some class it as one of the strongest benzodiazepines around – 
hence the lack of a license here. Even in Germany it should only be used for severe 
insomnia and short term – only 2-4 weeks. Otherwise you are addicted. Oh dear …’ 
(Daily Telegraph) 
Focus group members often talked about risks and benefits (n=13) when discussing  the 
media report and, like the posters, generally fell into one of two camps having weighed up the 
risks, as supportive of or rejecting sleeping pills.  Amongst those who saw the benefits as 
greater than the risks were those on hypnotics from the residential home who considered that 
at their time of life what was the point of taking them off these pills if their quality of life was 
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damaged as a result. For example, consider the following exchange amongst focus group 
members: 
 RFG1F6: ... doesn’t it matter at our age? 
 RFG1F1: Exactly it’s like telling a 99 year old to stop smoking 
RFG1F3: Yes, change your diet? Why?! 
RFG1F6: I’m not being morbid. I’d rather go early with a good life, feeling good. 
RFG1F7: There’s not much sense to living to 95 if you feel awful, isn’t it? 
Moderator: So you actually said you had seen this (news story) before. When you saw 
it what did you think? 
RFG1F7: I’d turned my back on it actually, at my age. Probably if you were younger 
you might take more notice of it but it didn’t impress me...It didn’t worry me that I 
would be popping my clogs earlier… I’d read everything that’s available and you just 
make your own judgement then, don’t you. 
.  As we can see the message of the media story was also discounted on the grounds of ‘age’ 
and ‘lay expertise’. Other focus group members who were not hypnotic users were more 
willing to accept the message of the media story, taking a more negative view of the risks in 
light of the contents of the newspaper article’. For example:  
 ‘I think it’s very serious. I didn’t realise it was as bad as that, you know when you 
read it. It’s worrying, isn’t it for people that take a lot of them. ..If I was on any of 
these, my God I’d be there (GP’s surgery) tomorrow (to discuss the risks)!’ (RFG2F4) 
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We can see in the above example how media coverage of medicines could perhaps contribute 
to a wider ‘de-pharmaceuticalisation’ agenda, by highlighting risks and inciting concern 
around the use of particular pharmaceutical products. In this case, however, awareness of the 
risks did not undermine trust in medical authority. Rather, the GP was seen as potentially a 
key source of advice.   
 
iv) Challenges to pharmaceuticalisation 
A fourth and final group of posters (n=47) took a markedly more critical stance. They aimed 
their criticism at both GPs for handing out hypnotics too easily and at the drug companies 
who they felt were primarily concerned with profit maximisation. Take, for example, a poster 
from the Guardian who opposed pharmaceutical solutions to health problems, including 
sleeplessness: 
‘Prescription drugs kill a lot of people in the USA every year. This is only the tip of 
the iceberg. The culture that has doctors reaching for their prescription pads for 
absolutely every real or imagined ill is long overdue a serious overhaul.’ 
Other posters aligned themselves with a de-pharmaceuticalisation agenda in recommending 
alternatives to hypnotics. These included herbal remedies, cognitive behaviour therapy (CBT) 
and even salt water. For example: 
‘Sleep experts say most mental illness is due to lack of, and poor, sleep. To get the 
sleep you get at the coast when the wind blows in from the sea, just heat salt water in 
an oil burner overnight. This cures insomnia in just five nights, and takes with it any 
symptoms of mental illness.’ (The Sun) 
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Occasionally a poster would express desire for de-pharmaceuticalisation of their own sleep 
but also the difficulty in achieving this without wider support for and access to non-
pharmaceutical treatments such as CBT. The poster below expresses exasperation for being 
refused CBT by a GP as an alternative to sleeping pills. While being critical of this state of 
affairs, sleeplessness was still being defined in medical terms as a problem that medicine 
might help alleviate:  
‘I returned to the doctors in January this year (after having previously been prescribed 
temazepam and Zopiclone) and asked about CBT (Cognitive Behavioural Therapy) as 
I don’t want to spend my life on sleeping pills... This was refused point blank - my 
doctor didn’t even seem to be aware it was a valid option for insomniacs, saying it 
was only for depression.’ (The Guardian) 
Focus group members who challenged pharmaceuticalistion (n=7), in contrast, were 
somewhat less critical and generally restricted themselves to claiming that the media 
coverage confirmed their view that prescriptions for sleeping tablets were too readily 
available from GPs and that, if they were still users, such coverage provided them with an 
increased incentive to stop taking the tablets. Consider the following exchange between a 
male and female participant from a primary care focus group and the group moderator: 
PCFG2M1: I think this is going to... just increase my incentive to get off these drugs 
by the end of the calendar year basically. Definitely I know, because of the way I feel 
that taking Zopiclone isn’t good for my body.  So I’ve got to go with that. 
Moderator: You had already heard the news story, did it stimulate you into checking it 
out any more at the time? 
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PCFG2 M1: Well I spoke to a friend who worked, until recently with mental health 
services.. and had a chat with her about.. 
Moderator: As a result of this news story?  
PCFG2M1: Yes, as a result of the news story and she said ‘I don’t know how many 
people are prescribed Zopiclone in this country but I bet it is millions’. I didn’t know 
what the figure was but I do now. I’m shocked actually, that it’s that high. She said a 
lot of this medication shouldn’t be prescribed in the first place and if it is should be 
very, very strictly monitored. A lot more should be done so that people don’t end up 
being addicted. 
Later in the discussion he continued: 
PCFG2M1: We probably all know that a little bit of something doesn’t tend to have a 
lasting harm. I’m not doing a little bit of Zopiclone, I’m doing it every day for years.. 
So I’ve got to do something about it. 
PCFG2F1: But print, actually having it in print, black and white, changes your 
attitude to the way you think, sometimes as well. So I mean, I would be… I could still 
go on for years and years and not be bloody questioned by my doctor, but because 
I’ve seen that perhaps I’ll question her now. But then I’m only on a small dose. 
In this case the male focus group member had already heard the story and said he had 
confided with a friend with clinical experience who reinforced the negative message that 
sleeping tablets were over prescribed and that more should be done to avoid patients getting 
addicted. The ‘addiction repertoire’ was thus employed rhetorically to support his claim that 
he intended to come off sleeping tablets as soon as possible. His view was endorsed by a 
female member of the focus group who said that the media story had changed her mind and 
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made her think about raising it with her GP, thus continuing to rely on medical authority,  
although she wanted to make it clear she was not a heavy user (and by implication not 
addicted). This is the only case in our two data sets where the media coverage of sleeping 
pills could be said to have challenged people’s world view and made them re-think, perhaps 
because there was a degree of consensus, in light of the media story, that withdrawing from 
long term hypnotic use was advisable.  
Interestingly, none of the focus group participants were critical of the pharmaceutical 
companies who made the sleeping tablets and only one group talked about cognitive 
behaviour therapy as an alternative but dismissed this on cost grounds, as reflected in the 
following exchange: 
 PCFG2M2: If they were to switch to this CBT… that costs more than pills.. 
 PCFG2M1: Someone is asking that question somewhere I guess. 
PFG2M2: If it costs more they won’t change, will they?... They will be spending more 
money when they’re supposed to be reducing…there is only so much pie, isn’t there? 
Here the possibility of de-pharmaceuticalisation through CBT is therefore considered but 
seen as unrealistic for economic reasons. This is in contrast to the poster above who reported 
being denied CBT by his GP. In both cases de-pharmaceuticalisation via CBT is seen as 
problematic.  
 
Discussion 
This paper has considered how a story about the long term risks of taking prescribed 
hypnotics first reported in the BMJ Open and then on websites of English national 
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newspapers and the British Broadcasting Corporation was responded to  through online 
comments (posts), and subsequently by members of focus groups. The paper is thus 
concerned with what some have called ‘short-term’ rather than ‘long-term effects’ of media 
coverage (see, for example, Hernandez et al 2012 for such a distinction). 
 
Overall we found that the dominant message of the media coverage of this story - that 
hypnotics enhance the risk of ‘premature death’ - did not seem to create alarm on the part of 
the different audiences. In the case of focus group members they generally appear to have 
responded in line with their existing views of hypnotics. As acknowledged previously, we are 
not able to make this claim about the posters as we do not know how they viewed sleeping 
pills before the press coverage of the BMJ Open article. 
 
This is not to say that the people in our study were all passive recipients of media reports.  On 
the contrary, as we have seen, there was strong evidence of resistance to the media story 
amongst some posters and focus group members. This took the form of criticising the 
reporting of the story as evidence of ‘bad’ science/journalism, continuing to claim that 
hypnotics were a necessity despite concerns reported in the media (a view expressed by users 
as far back as the early 1980s (Gabe and Lipshitz-Phillips 1982)) and drawing on lay 
knowledge and experience (Williams and Popay 2006) or lay pharmacology (Webster et al 
2009) to justify continued use. Repertoires such as the ‘deserving user’ and the ‘responsible 
user’ were called on to justify continued use while that of the ‘addict’ was drawn on to 
support withdrawal from use or non-use (Gabe et al 2016). There was indeed only one case 
where focus group members who were on hypnotics expressed a desire to withdraw or at 
least discuss that possibility with their doctor in light of the media story, perhaps reflecting a 
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degree of consensus in the group about the merits of de-pharmaceuticalisation in the face of 
addiction.  
The extent to which lay ‘expertise’ was drawn on in responding to the media story was one of 
the most striking findings of this study. People drew on their own or others’ experience of 
taking hypnotics to recognise the legitimacy of taking them or to weigh up the risks and 
benefits in true late modern style, as reflexive users (Williams and Calnan 1996). Posters in 
particular expressed scepticism about the scientific quality or methodological limits of the 
study and the difference between association and causation, apparently drawing on ubiquitous 
meta-expertise (Collins 2014). They were however a self-selected group which might explain 
in part at least the availability of such expertise.  It is also possible that some of them were 
not lay experts at all however, but scientists and experts of various kinds in their own right. 
which would explain the more sophisticated methodological critique of some of the posters, 
although again we have no concrete evidence to suggest that this was so. 
In terms of the wider issue of (de)pharmaceuticalisation, stories such as the one considered 
here can be seen as contributing to the de-pharmaceuticalisation of sleep agenda that has been 
emerging in the UK, with measures being put in place to reduce hypnotic prescribing in 
primary care and some encouragement of CBT from the UK government through the IAPT 
programme.  By framing the story in terms of the risks involved in taking sleeping pills the 
media may be able to raise public awareness of concern about them. In generating awareness 
of CBT as an alternative to hypnotics, de-pharmaceuticalisation of sleep is being promoted as 
a realistic possibility. This could be of particular significance given that a lot of people now 
get health related information directly from the media, online or through traditional media 
outlets (Broom and Tovey 2008, Nettleton 2004, Seale 2004), rather than from doctors.  
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At the same time we have seen that recipients of the media story about sleeping tablets were 
active and selective in their response to coverage of this issue, as one might expect given the 
literature on media audiences more generally (Seale 2004, Webster 2014). In this case we 
found that they often reacted in line with existing views and values, drawing on ubiquitous 
meta expertise (Collins 2014) or experiential/lay knowledge to corroborate or rebuff 
information made available to them; thereby in the process supporting pharmaceuticalisation 
or encouraging its reduction. This finding is similar to other research on people’s responses to 
health stories, such as that concerning  online commentators’ reaction to media stories 
challenging US guidelines on breastfeeding (Holton et al 2014, Len-Rios et al 2014). 
Consequently, it seems that negative stories about medications are not necessarily translated 
by people into messages to stop taking them or encouragement for de-pharmaceuticalisation. 
In our study there was only one occasion where this was so, but even then, the subsequent 
focus group discussion may have been more influential in encouraging the hypnotic user to 
consider cessation of the pills.  
Despite the media in this case presenting CBT as a non-pharmacological alternative to 
sleeping pills, thus making de-pharmaceuticalisation seem a realistic possibility, we found 
that when non-drug therapies like CBT were mentioned readers focused on the problems of 
access or effectiveness rather than seeing them as a realistic alternative to drugs. Moreover,  
access to therapy was still through doctors, thereby suggesting that it is possible to have the 
promotion of de-pharmaceuticalisation alongside continuing medicalisation. Further evidence 
for the continuation of medicalisation in the face of potential de-pharmaceuticalisation is 
provided by those focus group members who said that negative media coverage of sleeping 
tablets might lead them to seek advice from their doctor. 
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In sum, our case study cautions against making strong claims about the power of the media in 
encouraging or promoting de-pharmaceuticalisation. As Williams et al (2011) note, the mass 
media may be considered as ‘conveyors’ or ‘amplifiers’ of pharmaceuticalisation, rather than 
drivers of the process. The media’s negative framing of the hypnotics was generally 
interpreted in line with readers’ existing values, with the negative messages either being 
endorsed or challenged in line with their particular world view and non-pharmaceutical 
alternatives critically assessed rather than being unquestionably accepted as legitimate 
replacements for hypnotics   
This might go some way to explaining why, despite years of negative media coverage around 
sleeping pills, ambivalence about their use and evidence of widespread reluctance to take 
them in the general population (Gabe et al 2016 ), rates of use have remained relatively static. 
Media reporting on the risks and dangers of hypnotic use may strongly communicate and 
proliferate an anti-pharmaceuticalisation message. However, unlike media stories of new 
wonder drugs that promote pharmaceutical expansion and others which might fall under the 
umbrella of ‘disease mongering’ (Moynihan 2002), in cases of de-pharmaceuticalisation, the 
message is really only relevant to those whose sleep is already, or has been, 
pharmaceuticalised. These groups are therefore likely to hold pre-existing views regarding 
hypnotic use based on experiential knowledge and as our data suggests react to media stories 
in line with these views. Our analysis suggests that while the media may have a role as 
legitimators of de-pharmaceuticalisation, this is in the main only for those who are receptive 
to such a message already. 
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